Literature DB >> 3541203

Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL.

S S Clark, J McLaughlin, W M Crist, R Champlin, O N Witte.   

Abstract

In the Philadelphia chromosome (Ph1) of chronic myelogenous leukemia (CML), the c-abl gene on chromosome 9 is translocated to bcr on chromosome 22. This results in the expression of a chimeric bcr-abl message that encodes the P210bcr-abl tyrosine kinase. The cells of 10% of acute lymphocytic leukemia patients (ALL) carry a cytogenetically similar Ph1 translocation. We report that Ph1-positive ALL cells express unique abl-derived tyrosine kinases of 185 and 180 kilodaltons that are distinct from the bcr-abl-derived P210 protein of CML. The appearance of the 185/180-kilodalton proteins correlates with the expression of a novel 6.5-kilobase messenger RNA. Thus, similar genetic translocations in two different leukemias result in the expression of distinct c-abl-derived products.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3541203     DOI: 10.1126/science.3541203

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  52 in total

1.  Molecular biology of Philadelphia chromosome in chronic granulocytic leukaemia and acute lymphoblastic leukaemia.

Authors:  S Eridani; L M Wiedemann; L C Chan; R G Dalton; K K Karhi
Journal:  Cytotechnology       Date:  1987-10       Impact factor: 2.058

2.  BCR-ABL signaling: A new STATus in CML.

Authors:  Doriano Fabbro
Journal:  Nat Chem Biol       Date:  2012-02-15       Impact factor: 15.040

3.  The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.

Authors:  H Ahuja; M Bar-Eli; Z Arlin; S Advani; S L Allen; J Goldman; D Snyder; A Foti; M Cline
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

4.  Deciphering the Key Features of Malignant Tumor Microenvironment for Anti-cancer Therapy.

Authors:  Bingxue Shang; Gaochuan Zhang; Yanyan Pan; Quansheng Zhou
Journal:  Cancer Microenviron       Date:  2012-05-17

5.  Unique organization of the human BCR gene promoter.

Authors:  Q S Zhu; N Heisterkamp; J Groffen
Journal:  Nucleic Acids Res       Date:  1990-12-11       Impact factor: 16.971

Review 6.  Molecular analysis of the Philadelphia chromosome.

Authors:  A Dobrovic; G B Peters; J H Ford
Journal:  Chromosoma       Date:  1991-09       Impact factor: 4.316

7.  Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL.

Authors:  Charles G Mullighan; Richard T Williams; James R Downing; Charles J Sherr
Journal:  Genes Dev       Date:  2008-06-01       Impact factor: 11.361

8.  Localization of preferential sites of rearrangement within the BCR gene in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  C T Denny; N P Shah; S Ogden; C Willman; T McConnell; W Crist; A Carroll; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

9.  Lymphoid and mesenchymal tumors in transgenic mice expressing the v-fps protein-tyrosine kinase.

Authors:  S P Yee; D Mock; P Greer; V Maltby; J Rossant; A Bernstein; T Pawson
Journal:  Mol Cell Biol       Date:  1989-12       Impact factor: 4.272

10.  A 41-kilodalton protein is a potential substrate for the p210bcr-abl protein-tyrosine kinase in chronic myelogenous leukemia cells.

Authors:  E Freed; T Hunter
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.